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as a biomarker of rejection in kidney transplantation by
discussing the pathophysiology of C4d deposition on
erythrocytes (EC4d) and its potential value in clinical
transplantation. EC4d was described 40 years ago as the
determinant for the Chido and Rodgers blood groups. EC4d
was recently described as a marker of lupus activity2 and as
being related to alloantibody response in heart3 and lung4
transplantation. We recently showed that EC4d is a
noninvasive biomarker of antibody-mediated rejection in
kidney transplantation.5 EC4d levels paralleled donor-speciﬁc
anti-human leukocyte antibody occurrence, peritubular
capillary C4d staining, and were more predictive of
peritubular capillaritis, with better sensitivity, speciﬁcity,
and positive predictive value compared with peritubular
C4d. Interestingly, we observed that the major factor
determining the amount of C4d deposition is immunoglobu-
lin (Ig)G concentration. We found that C4d deposition on
erythrocytes in vitro can be triggered by changing the physical
conditions of the medium. We hypothesized that IgG
aggregation, owing to high sucrose concentration, initiates
C4d activation in vitro. C3d is another potential covalent
footprint that could be found in tissues and on erythrocytes in
the range of 1–3 log higher because of the C3 ampli-
ﬁcation loop.6 Surprisingly, C3d deposits are not detected or
may be detected at a very lower level than expected on
erythrocytes and in tissues. Another interesting issue is the
higher prevalence of C4d positivity in ABO-incompatible
renal allografts (almost invariably present) when compared
with positive cross-match transplants and recipients with
preformed donor-speciﬁc alloantibodies. The two immuno-
globulin classes are actually different in the two groups.
In ABO-incompatible transplants, natural IgM antibodies
that activate the complement are involved, as against anti-
human leukocyte IgG antibodies in positive cross-match
transplants. IgM antibodies are more efﬁcient in classical
complement pathway activation when compared with IgG
antibodies.7 IgM antibodies can also lead to C4d depo-
sition by the lectin pathway,8 thereby explaining the
excess C4d deposition in ABO-incompatible kidney trans-
plantation.
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Targeting K–ATP channel in
diabetic nephropathy: opening or
closing?
To the Editor: The effects of oral antidiabetic agents on
diabetic nephropathy have been thought to be due to their
ability to control blood glucose levels, and few studies have
examined whether these agents may also have direct effects on
the kidney.
Hung et al.1 have now examined the effect of three
different oral antidiabetic agents on renal outcome indepen-
dently of blood glucose control. The authors concluded that
sulfonylurea agents might not be desirable compared with
other treatments because of unfavorable renal effects.
However, these investigators did not give a speciﬁc reason
for why this is the case.
Sulfonylurea agents bind to its receptor (SUR), which is a
subunit of the ATP-dependent K channel. In pancreatic b-cells
the binding of sulfonylurea to SUR causes the K–ATP channel
to close, resulting in insulin secretion. In turn, another
subtype ‘SUR2’ is located in the kidney. In particular, SUR2
is expressed in mesangial cells, tubular epithelial cells, and
podocytes.2 Hence, it is conceivable that sulfonylurea could
act in the kidney.
In contrast to closing the K–ATP channel with sulfonyl-
urea, opening the channel is likely renoprotective. In fact,
iptakalim, a selective K–ATP channel opener, was found to
lower systemic blood pressure in association with endothelial
protection and lowering uric acid. Likewise, several research-
ers including our group demonstrated that opening of the
K–ATP channel with nicorandil contributes, along with its
ability to donate nitric oxide, to blocking the experimental
renal injury, including advanced diabetic nephropathy.2
Presumably, these lines of evidence could account for its
unfavorable effects in the kidney of type 2 diabetic subjects.
However, we should be aware that the effects of sulfo-
nylurea may be more complicated. Cortes’s3 research group
demonstrated that glibenclamide blocks high glucose–induced
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extracellular matrix formation, which might prevent diabetic
nephropathy.4 More studies are warranted to identify the best
therapeutic strategy for use of sulfonylurea in patients with
diabetic renal disease.
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Regarding Maas’s editorial letter
on serum suPAR levels
To the Editor: On the basis of data from a cohort of 23 adult
patients, the letter from Maas et al.1 concludes that serum
soluble urokinase–type plasminogen activator receptor
(suPAR) levels do not discriminate between primary focal
segmental glomerulosclerosis (FSGS), secondary FSGS, and
minimal change disease (MCD), and cannot be used to predict
the response to a therapeutic course of corticosteroids. They
further note an inverse correlation between the suPAR
concentration and estimated glomerular ﬁltration rate (eGFR).
We advise caution in the interpretation and application of
these ﬁndings for several reasons. First, the patients appear not
to be adequately characterized. For example, there is neither
comment about whether there was biopsy conﬁrmation of all
the cases with FSGS nor clariﬁcation of the criteria used to
distinguish primary from secondary FSGS. The patient with the
highest suPAR is categorized as having steroid-resistant MCD.
However, cross-referencing Figures 1 and 2 indicates that this
patient had the lowest eGFR, presumably o15ml/min. Such
an adverse renal function outcome is very unexpected in
patients with MCD and thus this patient is likely representative
of a FSGS case. Appropriate reclassiﬁcation of some of the
patients by Maas et al.2 may facilitate a more precise
comparison between suPAR and clinical outcomes. Second,
the authors’ conclusions are based on a small sample from a
single institution. In the original paper by Wei et al., data and
conclusions were based on a multicenter biopsy-proven cohort
including 78 pediatric and adult FSGS patients. In addition, we
have presented data from two large well-characterized patients
cohorts—the FSGS PodoNET and Clinical Trial—in which
55–85% of the patients with primary FSGS had an elevated
serum suPAR concentration.3 Although we welcome ongoing
investigation in this novel area, we suggest that information
collected in larger clinical studies involving well-phenotyped
patients should take precedence over data gathered in small
single-center studies where the phenotypic characterization
may be improved. Finally, we point out that MCD and FSGS
are classiﬁcations of diseases that lack speciﬁcity and that may
be amended with a molecular phenotyping approach involving
molecules such as suPAR. Using this strategy, patients with
elevated suPAR levels and poor renal outcomes may indeed
conﬁrm previous publications suggesting suPAR may be a
major cause of FSGS and a biomarker for a poor prognosis in
native and post-transplant recurrent FSGS and nephrotic
syndrome.
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